drugset / Trial / NCT04203914

Short Term Effect of Empagliflozin in Hypertension

NCT04203914

Phase 4 Completed 15 enrolled Yaounde Central Hospital
NaSingle-groupOpen-labelTreatment

Summary

The investigators assessed the 6-week effect of once daily 25mg SGLT2-i Empagliflozin on left ventricular diastolic function and blood pressure profile in non diabetic hypertensive patients

Timeline

Start
2017-01-10
Primary completion
2017-05-30
Completion
2017-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg

Indications